nodes	percent_of_prediction	percent_of_DWPC	metapath
Paricalcitol—CYP24A1—multiple sclerosis	0.566	0.763	CbGaD
Paricalcitol—VDR—multiple sclerosis	0.176	0.237	CbGaD
Paricalcitol—CYP3A4—Fingolimod—multiple sclerosis	0.0212	0.246	CbGbCtD
Paricalcitol—CYP3A4—Methylprednisolone—multiple sclerosis	0.0137	0.158	CbGbCtD
Paricalcitol—CYP3A4—Triamcinolone—multiple sclerosis	0.0104	0.12	CbGbCtD
Paricalcitol—CYP3A4—Mitoxantrone—multiple sclerosis	0.00999	0.116	CbGbCtD
Paricalcitol—CYP3A4—Betamethasone—multiple sclerosis	0.0089	0.103	CbGbCtD
Paricalcitol—CYP24A1—Vitamins—CYP27B1—multiple sclerosis	0.00886	0.137	CbGpPWpGaD
Paricalcitol—CYP3A4—Prednisolone—multiple sclerosis	0.00878	0.102	CbGbCtD
Paricalcitol—CYP3A4—Prednisone—multiple sclerosis	0.0083	0.0959	CbGbCtD
Paricalcitol—CYP24A1—Vitamin D (calciferol) metabolism—CYP27B1—multiple sclerosis	0.00783	0.121	CbGpPWpGaD
Paricalcitol—CYP24A1—Vitamin D Metabolism—CYP27B1—multiple sclerosis	0.00589	0.0907	CbGpPWpGaD
Paricalcitol—CYP3A4—Dexamethasone—multiple sclerosis	0.00518	0.0599	CbGbCtD
Paricalcitol—VDR—Vitamin D Metabolism—CYP24A1—multiple sclerosis	0.00494	0.076	CbGpPWpGaD
Paricalcitol—VDR—Vitamin D Metabolism—CYP27B1—multiple sclerosis	0.00494	0.076	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of steroid hormones and vitamin D—CYP27B1—multiple sclerosis	0.00227	0.0349	CbGpPWpGaD
Paricalcitol—CYP24A1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.00221	0.0341	CbGpPWpGaD
Paricalcitol—CYP24A1—Vitamin D Metabolism—VDR—multiple sclerosis	0.00193	0.0297	CbGpPWpGaD
Paricalcitol—VDR—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.00185	0.0286	CbGpPWpGaD
Paricalcitol—VDR—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.00185	0.0286	CbGpPWpGaD
Paricalcitol—CYP24A1—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.0014	0.0216	CbGpPWpGaD
Paricalcitol—CYP24A1—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.00139	0.0214	CbGpPWpGaD
Paricalcitol—CYP24A1—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.00114	0.0175	CbGpPWpGaD
Paricalcitol—Calcidiol—CYP27B1—multiple sclerosis	0.00105	0.133	CrCbGaD
Paricalcitol—Alfacalcidol—CYP27B1—multiple sclerosis	0.00105	0.133	CrCbGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—IL12A—multiple sclerosis	0.000963	0.0148	CbGpPWpGaD
Paricalcitol—VDR—Ovarian Infertility Genes—PGR—multiple sclerosis	0.000911	0.014	CbGpPWpGaD
Paricalcitol—Calcipotriol—CYP24A1—multiple sclerosis	0.000894	0.113	CrCbGaD
Paricalcitol—Calcidiol—CYP24A1—multiple sclerosis	0.000894	0.113	CrCbGaD
Paricalcitol—Calcitriol—CYP24A1—multiple sclerosis	0.000797	0.1	CrCbGaD
Paricalcitol—VDR—Nuclear Receptors—PGR—multiple sclerosis	0.000794	0.0122	CbGpPWpGaD
Paricalcitol—Ergocalciferol—CYP27B1—multiple sclerosis	0.000749	0.0945	CrCbGaD
Paricalcitol—CYP24A1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000724	0.0112	CbGpPWpGaD
Paricalcitol—Ergocalciferol—CYP24A1—multiple sclerosis	0.000637	0.0803	CrCbGaD
Paricalcitol—VDR—Nuclear Receptor transcription pathway—PGR—multiple sclerosis	0.000628	0.00967	CbGpPWpGaD
Paricalcitol—CYP24A1—Biological oxidations—CYP27B1—multiple sclerosis	0.000605	0.00932	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—IL12B—multiple sclerosis	0.000605	0.00931	CbGpPWpGaD
Paricalcitol—CYP24A1—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000597	0.00919	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of steroid hormones and vitamin D—POMC—multiple sclerosis	0.00051	0.00785	CbGpPWpGaD
Paricalcitol—UGT1A4—Biological oxidations—CYP27B1—multiple sclerosis	0.000484	0.00745	CbGpPWpGaD
Paricalcitol—UGT1A4—Biological oxidations—CYP24A1—multiple sclerosis	0.000484	0.00745	CbGpPWpGaD
Paricalcitol—UGT1A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000477	0.00735	CbGpPWpGaD
Paricalcitol—UGT1A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000477	0.00735	CbGpPWpGaD
Paricalcitol—Dihydrotachysterol—VDR—multiple sclerosis	0.00043	0.0543	CrCbGaD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—IFNB1—multiple sclerosis	0.000382	0.00588	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of TAp63 isoforms—FAS—multiple sclerosis	0.000365	0.00563	CbGpPWpGaD
Paricalcitol—VDR—Generic Transcription Pathway—ZNF746—multiple sclerosis	0.000359	0.00554	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—IRF5—multiple sclerosis	0.000338	0.0052	CbGpPWpGaD
Paricalcitol—CYP24A1—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000316	0.00487	CbGpPWpGaD
Paricalcitol—VDR—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—multiple sclerosis	0.000298	0.00459	CbGpPWpGaD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—IL10—multiple sclerosis	0.000295	0.00454	CbGpPWpGaD
Paricalcitol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000287	0.00442	CbGpPWpGaD
Paricalcitol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000287	0.00442	CbGpPWpGaD
Paricalcitol—VDR—RXR and RAR heterodimerization with other nuclear receptor—TNF—multiple sclerosis	0.000278	0.00429	CbGpPWpGaD
Paricalcitol—Calcidiol—VDR—multiple sclerosis	0.000277	0.035	CrCbGaD
Paricalcitol—Alfacalcidol—VDR—multiple sclerosis	0.000277	0.035	CrCbGaD
Paricalcitol—Calcipotriol—VDR—multiple sclerosis	0.000277	0.035	CrCbGaD
Paricalcitol—VDR—Retinoic acid receptors-mediated signaling—MAPK1—multiple sclerosis	0.000261	0.00402	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	0.00026	0.004	CbGpPWpGaD
Paricalcitol—CYP24A1—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000256	0.00395	CbGpPWpGaD
Paricalcitol—CYP3A4—Irinotecan Pathway—BCHE—multiple sclerosis	0.000254	0.00392	CbGpPWpGaD
Paricalcitol—Calcitriol—VDR—multiple sclerosis	0.000247	0.0312	CrCbGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000232	0.00358	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	0.000232	0.00357	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	0.000231	0.00356	CbGpPWpGaD
Paricalcitol—Ergocalciferol—VDR—multiple sclerosis	0.000198	0.0249	CrCbGaD
Paricalcitol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000182	0.00281	CbGpPWpGaD
Paricalcitol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000182	0.00281	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	0.00018	0.00278	CbGpPWpGaD
Paricalcitol—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.00018	0.00277	CbGpPWpGaD
Paricalcitol—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.00018	0.00277	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—SPP1—multiple sclerosis	0.000177	0.00272	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—ZNF746—multiple sclerosis	0.000173	0.00267	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—FAS—multiple sclerosis	0.000171	0.00263	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	0.000168	0.00259	CbGpPWpGaD
Paricalcitol—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000164	0.00252	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—PTBP1—multiple sclerosis	0.000158	0.00244	CbGpPWpGaD
Paricalcitol—Cholecalciferol—VDR—multiple sclerosis	0.00015	0.0189	CrCbGaD
Paricalcitol—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000148	0.00228	CbGpPWpGaD
Paricalcitol—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000148	0.00228	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—SRM—multiple sclerosis	0.000147	0.00226	CbGpPWpGaD
Paricalcitol—CYP24A1—Biological oxidations—POMC—multiple sclerosis	0.000136	0.0021	CbGpPWpGaD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—MYC—multiple sclerosis	0.00012	0.00185	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—HNRNPA1—multiple sclerosis	0.00012	0.00185	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—U2AF2—multiple sclerosis	0.00012	0.00185	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—SRM—multiple sclerosis	0.000117	0.00181	CbGpPWpGaD
Paricalcitol—UGT1A4—Biological oxidations—POMC—multiple sclerosis	0.000109	0.00168	CbGpPWpGaD
Paricalcitol—VDR—Generic Transcription Pathway—PGR—multiple sclerosis	0.000108	0.00167	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—CYP27B1—multiple sclerosis	0.000103	0.00159	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	0.000101	0.00156	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—ZFP36L1—multiple sclerosis	9.48e-05	0.00146	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—GPC5—multiple sclerosis	9.46e-05	0.00146	CbGpPWpGaD
Paricalcitol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	9.39e-05	0.00145	CbGpPWpGaD
Paricalcitol—Confusional state—Methylprednisolone—multiple sclerosis	8.56e-05	0.000867	CcSEcCtD
Paricalcitol—Immune system disorder—Prednisone—multiple sclerosis	8.55e-05	0.000866	CcSEcCtD
Paricalcitol—Malaise—Dexamethasone—multiple sclerosis	8.53e-05	0.000864	CcSEcCtD
Paricalcitol—Malaise—Betamethasone—multiple sclerosis	8.53e-05	0.000864	CcSEcCtD
Paricalcitol—Oedema—Triamcinolone—multiple sclerosis	8.51e-05	0.000862	CcSEcCtD
Paricalcitol—Vertigo—Dexamethasone—multiple sclerosis	8.5e-05	0.000861	CcSEcCtD
Paricalcitol—Vertigo—Betamethasone—multiple sclerosis	8.5e-05	0.000861	CcSEcCtD
Paricalcitol—Syncope—Betamethasone—multiple sclerosis	8.49e-05	0.000859	CcSEcCtD
Paricalcitol—Syncope—Dexamethasone—multiple sclerosis	8.49e-05	0.000859	CcSEcCtD
Paricalcitol—Arrhythmia—Prednisone—multiple sclerosis	8.46e-05	0.000856	CcSEcCtD
Paricalcitol—Infection—Triamcinolone—multiple sclerosis	8.46e-05	0.000856	CcSEcCtD
Paricalcitol—Sweating—Methotrexate—multiple sclerosis	8.45e-05	0.000856	CcSEcCtD
Paricalcitol—Infection—Methylprednisolone—multiple sclerosis	8.44e-05	0.000854	CcSEcCtD
Paricalcitol—Shock—Triamcinolone—multiple sclerosis	8.37e-05	0.000848	CcSEcCtD
Paricalcitol—Insomnia—Prednisolone—multiple sclerosis	8.37e-05	0.000848	CcSEcCtD
Paricalcitol—Alopecia—Prednisone—multiple sclerosis	8.36e-05	0.000847	CcSEcCtD
Paricalcitol—Shock—Methylprednisolone—multiple sclerosis	8.35e-05	0.000846	CcSEcCtD
Paricalcitol—Nervous system disorder—Methylprednisolone—multiple sclerosis	8.33e-05	0.000843	CcSEcCtD
Paricalcitol—Loss of consciousness—Betamethasone—multiple sclerosis	8.32e-05	0.000842	CcSEcCtD
Paricalcitol—Loss of consciousness—Dexamethasone—multiple sclerosis	8.32e-05	0.000842	CcSEcCtD
Paricalcitol—Epistaxis—Methotrexate—multiple sclerosis	8.31e-05	0.000842	CcSEcCtD
Paricalcitol—Hypersensitivity—Mitoxantrone—multiple sclerosis	8.31e-05	0.000842	CcSEcCtD
Paricalcitol—Paraesthesia—Prednisolone—multiple sclerosis	8.31e-05	0.000842	CcSEcCtD
Paricalcitol—Mental disorder—Prednisone—multiple sclerosis	8.29e-05	0.00084	CcSEcCtD
Paricalcitol—Nausea—Azathioprine—multiple sclerosis	8.29e-05	0.000839	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—CYP27B1—multiple sclerosis	8.27e-05	0.00127	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—CYP24A1—multiple sclerosis	8.27e-05	0.00127	CbGpPWpGaD
Paricalcitol—Skin disorder—Methylprednisolone—multiple sclerosis	8.25e-05	0.000835	CcSEcCtD
Paricalcitol—Malnutrition—Prednisone—multiple sclerosis	8.24e-05	0.000834	CcSEcCtD
Paricalcitol—Hyperhidrosis—Triamcinolone—multiple sclerosis	8.23e-05	0.000833	CcSEcCtD
Paricalcitol—Hyperhidrosis—Methylprednisolone—multiple sclerosis	8.21e-05	0.000831	CcSEcCtD
Paricalcitol—Hypertension—Dexamethasone—multiple sclerosis	8.17e-05	0.000827	CcSEcCtD
Paricalcitol—Hypertension—Betamethasone—multiple sclerosis	8.17e-05	0.000827	CcSEcCtD
Paricalcitol—Asthenia—Mitoxantrone—multiple sclerosis	8.09e-05	0.00082	CcSEcCtD
Paricalcitol—Myalgia—Dexamethasone—multiple sclerosis	8.06e-05	0.000816	CcSEcCtD
Paricalcitol—Myalgia—Betamethasone—multiple sclerosis	8.06e-05	0.000816	CcSEcCtD
Paricalcitol—Anxiety—Betamethasone—multiple sclerosis	8.03e-05	0.000813	CcSEcCtD
Paricalcitol—Anxiety—Dexamethasone—multiple sclerosis	8.03e-05	0.000813	CcSEcCtD
Paricalcitol—Discomfort—Betamethasone—multiple sclerosis	7.96e-05	0.000806	CcSEcCtD
Paricalcitol—Discomfort—Dexamethasone—multiple sclerosis	7.96e-05	0.000806	CcSEcCtD
Paricalcitol—Hypotension—Methylprednisolone—multiple sclerosis	7.94e-05	0.000804	CcSEcCtD
Paricalcitol—Pain—Prednisolone—multiple sclerosis	7.91e-05	0.000801	CcSEcCtD
Paricalcitol—Pharyngitis—Methotrexate—multiple sclerosis	7.85e-05	0.000795	CcSEcCtD
Paricalcitol—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	7.85e-05	0.00121	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	7.85e-05	0.00121	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—RRM1—multiple sclerosis	7.84e-05	0.00121	CbGpPWpGaD
Paricalcitol—Urinary tract disorder—Methotrexate—multiple sclerosis	7.81e-05	0.000791	CcSEcCtD
Paricalcitol—Urethral disorder—Methotrexate—multiple sclerosis	7.76e-05	0.000785	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	7.75e-05	0.000785	CcSEcCtD
Paricalcitol—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	7.74e-05	0.00119	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	7.74e-05	0.00119	CbGpPWpGaD
Paricalcitol—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	7.74e-05	0.000784	CcSEcCtD
Paricalcitol—Oedema—Betamethasone—multiple sclerosis	7.72e-05	0.000782	CcSEcCtD
Paricalcitol—Oedema—Dexamethasone—multiple sclerosis	7.72e-05	0.000782	CcSEcCtD
Paricalcitol—Diarrhoea—Mitoxantrone—multiple sclerosis	7.72e-05	0.000782	CcSEcCtD
Paricalcitol—Insomnia—Triamcinolone—multiple sclerosis	7.7e-05	0.00078	CcSEcCtD
Paricalcitol—Insomnia—Methylprednisolone—multiple sclerosis	7.68e-05	0.000778	CcSEcCtD
Paricalcitol—Infection—Betamethasone—multiple sclerosis	7.67e-05	0.000777	CcSEcCtD
Paricalcitol—Infection—Dexamethasone—multiple sclerosis	7.67e-05	0.000777	CcSEcCtD
Paricalcitol—Ill-defined disorder—Prednisone—multiple sclerosis	7.65e-05	0.000774	CcSEcCtD
Paricalcitol—Paraesthesia—Triamcinolone—multiple sclerosis	7.64e-05	0.000774	CcSEcCtD
Paricalcitol—Feeling abnormal—Prednisolone—multiple sclerosis	7.63e-05	0.000772	CcSEcCtD
Paricalcitol—Paraesthesia—Methylprednisolone—multiple sclerosis	7.63e-05	0.000772	CcSEcCtD
Paricalcitol—Anaemia—Prednisone—multiple sclerosis	7.62e-05	0.000771	CcSEcCtD
Paricalcitol—Shock—Dexamethasone—multiple sclerosis	7.6e-05	0.000769	CcSEcCtD
Paricalcitol—Shock—Betamethasone—multiple sclerosis	7.6e-05	0.000769	CcSEcCtD
Paricalcitol—Dyspnoea—Triamcinolone—multiple sclerosis	7.59e-05	0.000768	CcSEcCtD
Paricalcitol—Nervous system disorder—Dexamethasone—multiple sclerosis	7.57e-05	0.000767	CcSEcCtD
Paricalcitol—Nervous system disorder—Betamethasone—multiple sclerosis	7.57e-05	0.000767	CcSEcCtD
Paricalcitol—Agitation—Prednisone—multiple sclerosis	7.57e-05	0.000767	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—GPC5—multiple sclerosis	7.56e-05	0.00117	CbGpPWpGaD
Paricalcitol—Angioedema—Prednisone—multiple sclerosis	7.53e-05	0.000763	CcSEcCtD
Paricalcitol—Dyspepsia—Triamcinolone—multiple sclerosis	7.49e-05	0.000759	CcSEcCtD
Paricalcitol—Dyspepsia—Methylprednisolone—multiple sclerosis	7.48e-05	0.000757	CcSEcCtD
Paricalcitol—Hyperhidrosis—Betamethasone—multiple sclerosis	7.47e-05	0.000756	CcSEcCtD
Paricalcitol—Hyperhidrosis—Dexamethasone—multiple sclerosis	7.47e-05	0.000756	CcSEcCtD
Paricalcitol—Malaise—Prednisone—multiple sclerosis	7.43e-05	0.000753	CcSEcCtD
Paricalcitol—Vertigo—Prednisone—multiple sclerosis	7.4e-05	0.00075	CcSEcCtD
Paricalcitol—Eye disorder—Methotrexate—multiple sclerosis	7.39e-05	0.000749	CcSEcCtD
Paricalcitol—Syncope—Prednisone—multiple sclerosis	7.39e-05	0.000748	CcSEcCtD
Paricalcitol—Anorexia—Dexamethasone—multiple sclerosis	7.36e-05	0.000745	CcSEcCtD
Paricalcitol—Anorexia—Betamethasone—multiple sclerosis	7.36e-05	0.000745	CcSEcCtD
Paricalcitol—Urticaria—Prednisolone—multiple sclerosis	7.35e-05	0.000745	CcSEcCtD
Paricalcitol—VDR—Gene Expression—PABPC1—multiple sclerosis	7.35e-05	0.00113	CbGpPWpGaD
Paricalcitol—Cardiac disorder—Methotrexate—multiple sclerosis	7.34e-05	0.000744	CcSEcCtD
Paricalcitol—Fatigue—Triamcinolone—multiple sclerosis	7.34e-05	0.000743	CcSEcCtD
Paricalcitol—Fatigue—Methylprednisolone—multiple sclerosis	7.32e-05	0.000741	CcSEcCtD
Paricalcitol—Pain—Triamcinolone—multiple sclerosis	7.28e-05	0.000737	CcSEcCtD
Paricalcitol—Loss of consciousness—Prednisone—multiple sclerosis	7.24e-05	0.000733	CcSEcCtD
Paricalcitol—Hypotension—Dexamethasone—multiple sclerosis	7.22e-05	0.000731	CcSEcCtD
Paricalcitol—Hypotension—Betamethasone—multiple sclerosis	7.22e-05	0.000731	CcSEcCtD
Paricalcitol—Angiopathy—Methotrexate—multiple sclerosis	7.18e-05	0.000727	CcSEcCtD
Paricalcitol—Vomiting—Mitoxantrone—multiple sclerosis	7.17e-05	0.000726	CcSEcCtD
Paricalcitol—UGT1A4—NRF2 pathway—TGFB1—multiple sclerosis	7.15e-05	0.0011	CbGpPWpGaD
Paricalcitol—Immune system disorder—Methotrexate—multiple sclerosis	7.15e-05	0.000724	CcSEcCtD
Paricalcitol—Mediastinal disorder—Methotrexate—multiple sclerosis	7.13e-05	0.000722	CcSEcCtD
Paricalcitol—Hypertension—Prednisone—multiple sclerosis	7.11e-05	0.00072	CcSEcCtD
Paricalcitol—Rash—Mitoxantrone—multiple sclerosis	7.11e-05	0.00072	CcSEcCtD
Paricalcitol—Dermatitis—Mitoxantrone—multiple sclerosis	7.11e-05	0.00072	CcSEcCtD
Paricalcitol—Chills—Methotrexate—multiple sclerosis	7.1e-05	0.000719	CcSEcCtD
Paricalcitol—Headache—Mitoxantrone—multiple sclerosis	7.07e-05	0.000716	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	7.04e-05	0.000713	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	7.04e-05	0.000713	CcSEcCtD
Paricalcitol—Arthralgia—Prednisone—multiple sclerosis	7.02e-05	0.00071	CcSEcCtD
Paricalcitol—Myalgia—Prednisone—multiple sclerosis	7.02e-05	0.00071	CcSEcCtD
Paricalcitol—Feeling abnormal—Triamcinolone—multiple sclerosis	7.01e-05	0.00071	CcSEcCtD
Paricalcitol—Feeling abnormal—Methylprednisolone—multiple sclerosis	7e-05	0.000709	CcSEcCtD
Paricalcitol—Anxiety—Prednisone—multiple sclerosis	6.99e-05	0.000708	CcSEcCtD
Paricalcitol—Alopecia—Methotrexate—multiple sclerosis	6.99e-05	0.000708	CcSEcCtD
Paricalcitol—Insomnia—Dexamethasone—multiple sclerosis	6.98e-05	0.000707	CcSEcCtD
Paricalcitol—Insomnia—Betamethasone—multiple sclerosis	6.98e-05	0.000707	CcSEcCtD
Paricalcitol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	6.97e-05	0.000706	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	6.94e-05	0.000703	CcSEcCtD
Paricalcitol—Paraesthesia—Dexamethasone—multiple sclerosis	6.93e-05	0.000702	CcSEcCtD
Paricalcitol—Paraesthesia—Betamethasone—multiple sclerosis	6.93e-05	0.000702	CcSEcCtD
Paricalcitol—Discomfort—Prednisone—multiple sclerosis	6.93e-05	0.000702	CcSEcCtD
Paricalcitol—Mental disorder—Methotrexate—multiple sclerosis	6.93e-05	0.000702	CcSEcCtD
Paricalcitol—Malnutrition—Methotrexate—multiple sclerosis	6.89e-05	0.000697	CcSEcCtD
Paricalcitol—Hypersensitivity—Prednisolone—multiple sclerosis	6.82e-05	0.000691	CcSEcCtD
Paricalcitol—Dyspepsia—Betamethasone—multiple sclerosis	6.8e-05	0.000688	CcSEcCtD
Paricalcitol—Dyspepsia—Dexamethasone—multiple sclerosis	6.8e-05	0.000688	CcSEcCtD
Paricalcitol—Urticaria—Triamcinolone—multiple sclerosis	6.76e-05	0.000685	CcSEcCtD
Paricalcitol—Urticaria—Methylprednisolone—multiple sclerosis	6.75e-05	0.000683	CcSEcCtD
Paricalcitol—Dysgeusia—Methotrexate—multiple sclerosis	6.74e-05	0.000683	CcSEcCtD
Paricalcitol—Body temperature increased—Triamcinolone—multiple sclerosis	6.73e-05	0.000681	CcSEcCtD
Paricalcitol—Oedema—Prednisone—multiple sclerosis	6.73e-05	0.000681	CcSEcCtD
Paricalcitol—Abdominal pain—Methylprednisolone—multiple sclerosis	6.71e-05	0.00068	CcSEcCtD
Paricalcitol—Decreased appetite—Betamethasone—multiple sclerosis	6.71e-05	0.00068	CcSEcCtD
Paricalcitol—Decreased appetite—Dexamethasone—multiple sclerosis	6.71e-05	0.00068	CcSEcCtD
Paricalcitol—Nausea—Mitoxantrone—multiple sclerosis	6.7e-05	0.000679	CcSEcCtD
Paricalcitol—Infection—Prednisone—multiple sclerosis	6.68e-05	0.000677	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	6.67e-05	0.000675	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Betamethasone—multiple sclerosis	6.67e-05	0.000675	CcSEcCtD
Paricalcitol—Back pain—Methotrexate—multiple sclerosis	6.66e-05	0.000675	CcSEcCtD
Paricalcitol—Fatigue—Betamethasone—multiple sclerosis	6.66e-05	0.000674	CcSEcCtD
Paricalcitol—Fatigue—Dexamethasone—multiple sclerosis	6.66e-05	0.000674	CcSEcCtD
Paricalcitol—VDR—Gene Expression—RPL5—multiple sclerosis	6.63e-05	0.00102	CbGpPWpGaD
Paricalcitol—Shock—Prednisone—multiple sclerosis	6.62e-05	0.00067	CcSEcCtD
Paricalcitol—Pain—Dexamethasone—multiple sclerosis	6.6e-05	0.000669	CcSEcCtD
Paricalcitol—Pain—Betamethasone—multiple sclerosis	6.6e-05	0.000669	CcSEcCtD
Paricalcitol—Nervous system disorder—Prednisone—multiple sclerosis	6.6e-05	0.000668	CcSEcCtD
Paricalcitol—Skin disorder—Prednisone—multiple sclerosis	6.53e-05	0.000662	CcSEcCtD
Paricalcitol—Hyperhidrosis—Prednisone—multiple sclerosis	6.5e-05	0.000658	CcSEcCtD
Paricalcitol—Anorexia—Prednisone—multiple sclerosis	6.41e-05	0.000649	CcSEcCtD
Paricalcitol—Ill-defined disorder—Methotrexate—multiple sclerosis	6.39e-05	0.000647	CcSEcCtD
Paricalcitol—Anaemia—Methotrexate—multiple sclerosis	6.37e-05	0.000645	CcSEcCtD
Paricalcitol—Feeling abnormal—Betamethasone—multiple sclerosis	6.36e-05	0.000644	CcSEcCtD
Paricalcitol—Feeling abnormal—Dexamethasone—multiple sclerosis	6.36e-05	0.000644	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Dexamethasone—multiple sclerosis	6.31e-05	0.00064	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Betamethasone—multiple sclerosis	6.31e-05	0.00064	CcSEcCtD
Paricalcitol—Hypersensitivity—Triamcinolone—multiple sclerosis	6.27e-05	0.000635	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—RRM1—multiple sclerosis	6.27e-05	0.000966	CbGpPWpGaD
Paricalcitol—Hypersensitivity—Methylprednisolone—multiple sclerosis	6.26e-05	0.000634	CcSEcCtD
Paricalcitol—Malaise—Methotrexate—multiple sclerosis	6.21e-05	0.000629	CcSEcCtD
Paricalcitol—Vertigo—Methotrexate—multiple sclerosis	6.19e-05	0.000627	CcSEcCtD
Paricalcitol—Leukopenia—Methotrexate—multiple sclerosis	6.16e-05	0.000624	CcSEcCtD
Paricalcitol—Urticaria—Dexamethasone—multiple sclerosis	6.13e-05	0.000621	CcSEcCtD
Paricalcitol—Urticaria—Betamethasone—multiple sclerosis	6.13e-05	0.000621	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Prednisone—multiple sclerosis	6.13e-05	0.000621	CcSEcCtD
Paricalcitol—Dizziness—Prednisolone—multiple sclerosis	6.12e-05	0.00062	CcSEcCtD
Paricalcitol—Asthenia—Triamcinolone—multiple sclerosis	6.11e-05	0.000618	CcSEcCtD
Paricalcitol—Abdominal pain—Dexamethasone—multiple sclerosis	6.1e-05	0.000618	CcSEcCtD
Paricalcitol—Body temperature increased—Betamethasone—multiple sclerosis	6.1e-05	0.000618	CcSEcCtD
Paricalcitol—Abdominal pain—Betamethasone—multiple sclerosis	6.1e-05	0.000618	CcSEcCtD
Paricalcitol—Body temperature increased—Dexamethasone—multiple sclerosis	6.1e-05	0.000618	CcSEcCtD
Paricalcitol—Asthenia—Methylprednisolone—multiple sclerosis	6.09e-05	0.000617	CcSEcCtD
Paricalcitol—Insomnia—Prednisone—multiple sclerosis	6.08e-05	0.000616	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	6.08e-05	0.000937	CbGpPWpGaD
Paricalcitol—Paraesthesia—Prednisone—multiple sclerosis	6.04e-05	0.000612	CcSEcCtD
Paricalcitol—Pruritus—Triamcinolone—multiple sclerosis	6.02e-05	0.00061	CcSEcCtD
Paricalcitol—Cough—Methotrexate—multiple sclerosis	6.01e-05	0.000609	CcSEcCtD
Paricalcitol—Pruritus—Methylprednisolone—multiple sclerosis	6.01e-05	0.000608	CcSEcCtD
Paricalcitol—Dyspepsia—Prednisone—multiple sclerosis	5.92e-05	0.0006	CcSEcCtD
Paricalcitol—Chest pain—Methotrexate—multiple sclerosis	5.86e-05	0.000594	CcSEcCtD
Paricalcitol—Arthralgia—Methotrexate—multiple sclerosis	5.86e-05	0.000594	CcSEcCtD
Paricalcitol—Myalgia—Methotrexate—multiple sclerosis	5.86e-05	0.000594	CcSEcCtD
Paricalcitol—Decreased appetite—Prednisone—multiple sclerosis	5.85e-05	0.000592	CcSEcCtD
Paricalcitol—Rash—Prednisolone—multiple sclerosis	5.84e-05	0.000591	CcSEcCtD
Paricalcitol—Dermatitis—Prednisolone—multiple sclerosis	5.83e-05	0.00059	CcSEcCtD
Paricalcitol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	5.82e-05	0.00059	CcSEcCtD
Paricalcitol—Diarrhoea—Methylprednisolone—multiple sclerosis	5.81e-05	0.000588	CcSEcCtD
Paricalcitol—Fatigue—Prednisone—multiple sclerosis	5.8e-05	0.000587	CcSEcCtD
Paricalcitol—Headache—Prednisolone—multiple sclerosis	5.8e-05	0.000587	CcSEcCtD
Paricalcitol—Discomfort—Methotrexate—multiple sclerosis	5.79e-05	0.000587	CcSEcCtD
Paricalcitol—Constipation—Prednisone—multiple sclerosis	5.75e-05	0.000582	CcSEcCtD
Paricalcitol—Confusional state—Methotrexate—multiple sclerosis	5.67e-05	0.000574	CcSEcCtD
Paricalcitol—Dizziness—Triamcinolone—multiple sclerosis	5.63e-05	0.00057	CcSEcCtD
Paricalcitol—Dizziness—Methylprednisolone—multiple sclerosis	5.62e-05	0.000569	CcSEcCtD
Paricalcitol—Infection—Methotrexate—multiple sclerosis	5.58e-05	0.000565	CcSEcCtD
Paricalcitol—Feeling abnormal—Prednisone—multiple sclerosis	5.54e-05	0.000561	CcSEcCtD
Paricalcitol—Asthenia—Betamethasone—multiple sclerosis	5.54e-05	0.000561	CcSEcCtD
Paricalcitol—Asthenia—Dexamethasone—multiple sclerosis	5.54e-05	0.000561	CcSEcCtD
Paricalcitol—Nervous system disorder—Methotrexate—multiple sclerosis	5.51e-05	0.000558	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Prednisone—multiple sclerosis	5.5e-05	0.000557	CcSEcCtD
Paricalcitol—Nausea—Prednisolone—multiple sclerosis	5.5e-05	0.000557	CcSEcCtD
Paricalcitol—Pruritus—Dexamethasone—multiple sclerosis	5.46e-05	0.000553	CcSEcCtD
Paricalcitol—Pruritus—Betamethasone—multiple sclerosis	5.46e-05	0.000553	CcSEcCtD
Paricalcitol—Skin disorder—Methotrexate—multiple sclerosis	5.46e-05	0.000553	CcSEcCtD
Paricalcitol—Hyperhidrosis—Methotrexate—multiple sclerosis	5.43e-05	0.00055	CcSEcCtD
Paricalcitol—Vomiting—Triamcinolone—multiple sclerosis	5.41e-05	0.000548	CcSEcCtD
Paricalcitol—Vomiting—Methylprednisolone—multiple sclerosis	5.4e-05	0.000547	CcSEcCtD
Paricalcitol—Rash—Triamcinolone—multiple sclerosis	5.37e-05	0.000543	CcSEcCtD
Paricalcitol—Dermatitis—Triamcinolone—multiple sclerosis	5.36e-05	0.000543	CcSEcCtD
Paricalcitol—Anorexia—Methotrexate—multiple sclerosis	5.36e-05	0.000543	CcSEcCtD
Paricalcitol—Rash—Methylprednisolone—multiple sclerosis	5.35e-05	0.000542	CcSEcCtD
Paricalcitol—Dermatitis—Methylprednisolone—multiple sclerosis	5.35e-05	0.000542	CcSEcCtD
Paricalcitol—Urticaria—Prednisone—multiple sclerosis	5.34e-05	0.000541	CcSEcCtD
Paricalcitol—Headache—Triamcinolone—multiple sclerosis	5.33e-05	0.00054	CcSEcCtD
Paricalcitol—Headache—Methylprednisolone—multiple sclerosis	5.32e-05	0.000539	CcSEcCtD
Paricalcitol—Body temperature increased—Prednisone—multiple sclerosis	5.32e-05	0.000538	CcSEcCtD
Paricalcitol—Abdominal pain—Prednisone—multiple sclerosis	5.32e-05	0.000538	CcSEcCtD
Paricalcitol—Diarrhoea—Dexamethasone—multiple sclerosis	5.28e-05	0.000535	CcSEcCtD
Paricalcitol—Diarrhoea—Betamethasone—multiple sclerosis	5.28e-05	0.000535	CcSEcCtD
Paricalcitol—Hypotension—Methotrexate—multiple sclerosis	5.25e-05	0.000532	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	5.23e-05	0.000805	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—PGR—multiple sclerosis	5.22e-05	0.000804	CbGpPWpGaD
Paricalcitol—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	5.12e-05	0.000519	CcSEcCtD
Paricalcitol—Dizziness—Betamethasone—multiple sclerosis	5.11e-05	0.000517	CcSEcCtD
Paricalcitol—Dizziness—Dexamethasone—multiple sclerosis	5.11e-05	0.000517	CcSEcCtD
Paricalcitol—Insomnia—Methotrexate—multiple sclerosis	5.08e-05	0.000515	CcSEcCtD
Paricalcitol—Nausea—Triamcinolone—multiple sclerosis	5.06e-05	0.000512	CcSEcCtD
Paricalcitol—Paraesthesia—Methotrexate—multiple sclerosis	5.05e-05	0.000511	CcSEcCtD
Paricalcitol—Nausea—Methylprednisolone—multiple sclerosis	5.04e-05	0.000511	CcSEcCtD
Paricalcitol—Dyspnoea—Methotrexate—multiple sclerosis	5.01e-05	0.000507	CcSEcCtD
Paricalcitol—Somnolence—Methotrexate—multiple sclerosis	5e-05	0.000506	CcSEcCtD
Paricalcitol—Hypersensitivity—Prednisone—multiple sclerosis	4.95e-05	0.000502	CcSEcCtD
Paricalcitol—Dyspepsia—Methotrexate—multiple sclerosis	4.95e-05	0.000501	CcSEcCtD
Paricalcitol—Vomiting—Dexamethasone—multiple sclerosis	4.91e-05	0.000497	CcSEcCtD
Paricalcitol—Vomiting—Betamethasone—multiple sclerosis	4.91e-05	0.000497	CcSEcCtD
Paricalcitol—Decreased appetite—Methotrexate—multiple sclerosis	4.89e-05	0.000495	CcSEcCtD
Paricalcitol—Rash—Dexamethasone—multiple sclerosis	4.87e-05	0.000493	CcSEcCtD
Paricalcitol—Rash—Betamethasone—multiple sclerosis	4.87e-05	0.000493	CcSEcCtD
Paricalcitol—Dermatitis—Dexamethasone—multiple sclerosis	4.86e-05	0.000493	CcSEcCtD
Paricalcitol—Dermatitis—Betamethasone—multiple sclerosis	4.86e-05	0.000493	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Methotrexate—multiple sclerosis	4.85e-05	0.000491	CcSEcCtD
Paricalcitol—Fatigue—Methotrexate—multiple sclerosis	4.85e-05	0.000491	CcSEcCtD
Paricalcitol—Headache—Dexamethasone—multiple sclerosis	4.84e-05	0.00049	CcSEcCtD
Paricalcitol—Headache—Betamethasone—multiple sclerosis	4.84e-05	0.00049	CcSEcCtD
Paricalcitol—Asthenia—Prednisone—multiple sclerosis	4.83e-05	0.000489	CcSEcCtD
Paricalcitol—Pain—Methotrexate—multiple sclerosis	4.81e-05	0.000487	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	4.76e-05	0.000734	CbGpPWpGaD
Paricalcitol—Pruritus—Prednisone—multiple sclerosis	4.76e-05	0.000482	CcSEcCtD
Paricalcitol—Feeling abnormal—Methotrexate—multiple sclerosis	4.63e-05	0.000469	CcSEcCtD
Paricalcitol—Diarrhoea—Prednisone—multiple sclerosis	4.6e-05	0.000466	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Methotrexate—multiple sclerosis	4.6e-05	0.000465	CcSEcCtD
Paricalcitol—Nausea—Betamethasone—multiple sclerosis	4.59e-05	0.000465	CcSEcCtD
Paricalcitol—Nausea—Dexamethasone—multiple sclerosis	4.59e-05	0.000465	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—BCHE—multiple sclerosis	4.5e-05	0.000694	CbGpPWpGaD
Paricalcitol—Urticaria—Methotrexate—multiple sclerosis	4.47e-05	0.000452	CcSEcCtD
Paricalcitol—Dizziness—Prednisone—multiple sclerosis	4.45e-05	0.00045	CcSEcCtD
Paricalcitol—Body temperature increased—Methotrexate—multiple sclerosis	4.44e-05	0.00045	CcSEcCtD
Paricalcitol—Abdominal pain—Methotrexate—multiple sclerosis	4.44e-05	0.00045	CcSEcCtD
Paricalcitol—Vomiting—Prednisone—multiple sclerosis	4.28e-05	0.000433	CcSEcCtD
Paricalcitol—Rash—Prednisone—multiple sclerosis	4.24e-05	0.000429	CcSEcCtD
Paricalcitol—Dermatitis—Prednisone—multiple sclerosis	4.24e-05	0.000429	CcSEcCtD
Paricalcitol—Headache—Prednisone—multiple sclerosis	4.21e-05	0.000427	CcSEcCtD
Paricalcitol—Hypersensitivity—Methotrexate—multiple sclerosis	4.14e-05	0.000419	CcSEcCtD
Paricalcitol—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	4.1e-05	0.000632	CbGpPWpGaD
Paricalcitol—Asthenia—Methotrexate—multiple sclerosis	4.03e-05	0.000408	CcSEcCtD
Paricalcitol—Nausea—Prednisone—multiple sclerosis	3.99e-05	0.000405	CcSEcCtD
Paricalcitol—Pruritus—Methotrexate—multiple sclerosis	3.98e-05	0.000403	CcSEcCtD
Paricalcitol—Diarrhoea—Methotrexate—multiple sclerosis	3.85e-05	0.000389	CcSEcCtD
Paricalcitol—Dizziness—Methotrexate—multiple sclerosis	3.72e-05	0.000376	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—BCHE—multiple sclerosis	3.6e-05	0.000555	CbGpPWpGaD
Paricalcitol—Vomiting—Methotrexate—multiple sclerosis	3.57e-05	0.000362	CcSEcCtD
Paricalcitol—Rash—Methotrexate—multiple sclerosis	3.54e-05	0.000359	CcSEcCtD
Paricalcitol—Dermatitis—Methotrexate—multiple sclerosis	3.54e-05	0.000359	CcSEcCtD
Paricalcitol—Headache—Methotrexate—multiple sclerosis	3.52e-05	0.000357	CcSEcCtD
Paricalcitol—Nausea—Methotrexate—multiple sclerosis	3.34e-05	0.000338	CcSEcCtD
Paricalcitol—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	3.32e-05	0.000512	CbGpPWpGaD
Paricalcitol—VDR—Generic Transcription Pathway—MYC—multiple sclerosis	3.01e-05	0.000464	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—APOE—multiple sclerosis	2.71e-05	0.000417	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—POMC—multiple sclerosis	2.33e-05	0.000358	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—APOE—multiple sclerosis	2.17e-05	0.000334	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—ALB—multiple sclerosis	2.12e-05	0.000327	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—SRM—multiple sclerosis	1.91e-05	0.000294	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—POMC—multiple sclerosis	1.86e-05	0.000287	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—POMC—multiple sclerosis	1.77e-05	0.000272	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—ALB—multiple sclerosis	1.7e-05	0.000261	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—MYC—multiple sclerosis	1.45e-05	0.000223	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	1.34e-05	0.000207	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	1.34e-05	0.000207	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GPC5—multiple sclerosis	1.23e-05	0.000189	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—RRM1—multiple sclerosis	1.02e-05	0.000157	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—BCHE—multiple sclerosis	5.84e-06	9e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—APOE—multiple sclerosis	3.52e-06	5.42e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—POMC—multiple sclerosis	3.02e-06	4.65e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—ALB—multiple sclerosis	2.75e-06	4.24e-05	CbGpPWpGaD
